Direct Oral Anticoagulant Use in Older Adults with Atrial Fibrillation: Challenges and Solutions

Area of Science:

• Cardiology
• Geriatrics
• Pharmacology

Background:

• Atrial fibrillation (AF) is a common arrhythmia, particularly in older adults (>75 years).
• Stroke is a major complication of AF, leading to significant morbidity and mortality.
• Anticoagulation is crucial for stroke prevention but is underutilized due to bleeding concerns, especially intracerebral hemorrhage.

Purpose of the Study:

• To review the role of anticoagulation in stroke prevention for older adults with AF.
• To compare the benefits and drawbacks of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) in this population.
• To explore emerging anticoagulation strategies like Factor XI inhibition.

Main Methods:

• Review of clinical practice guidelines and existing literature on anticoagulation in AF.
• Analysis of the advantages and disadvantages of DOACs in older patients, including bleeding risk, monitoring, drug interactions, and dosing.
• Discussion of the limitations of current evidence and the potential of novel anticoagulants.

Main Results:

• DOACs have demonstrated a reduction in major bleeding events compared to VKAs.
• Advantages of DOACs in older patients include simplified monitoring and reduced risk of intracerebral hemorrhage.
• Disadvantages include potential for multiple daily doses and lack of a universal antidote for DOACs.

Conclusions:

• While DOACs offer benefits for stroke prevention in older adults with AF, definitive conclusions on the ideal DOAC are limited by a lack of head-to-head trials and specific studies in this demographic.
• Factor XI inhibition presents a promising new approach to anticoagulation with the potential to further reduce bleeding risk in the elderly.